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Abstract
Introduction Knowledge about the influence of current
neuroprotective interventions on prognostic markers after
survival from cardiac arrest is lacking. This study aimed to
investigate the effects of mild therapeutic hypothermia on the
release of the astroglial protein S-100 after cardiopulmonary
resuscitation (CPR) in survivors of out-of-hospital cardiac arrest.
Methods This was a prospective, observational study
performed during a two-year period, involving medical
emergency services and five collaborating hospitals at the city of
Aachen, Germany. Sixty-eight subjects were enrolled by the
emergency physician on duty by taking blood samples after
successful attempts at resuscitation with return of spontaneous
circulation (ROSC), followed by samples at 6, 12, 24, 72 and
120 hours post ROSC by the appropriate intensive care unit
staff. Depending on the decision of the attending physician,
subjects were cooled down to 33°C (n = 37) for 24 hours or
were held at 37°C (n = 31). Patients were tracked for estimating
mortality and gross neurological outcome for 14 days.
Results S-100 levels in patients not receiving mild therapeutic
hypothermia (normothermia (NT)) showed equivalent numbers
as compared with cooled patients (mild therapeutic hypothermia
(MTH)) on baseline (NT = 1.38 μg/l versus MTH = 1.30 μg/l; P
= 0.886). S-100 levels on baseline were significantly lower in
patients with a good neurological outcome at 14 days after the
event in comparison to their peers with adverse outcome (P =
0.014). Although the difference in S-100 levels of MTH patients
with adverse or favourable neurological outcome reached
statistical significance, it did not in NT patients.
Conclusions Although the predictive power of S-100 levels
were best on admission but not at later time points, MTH had no
influence on S-100 serum levels in survivors of non-traumatic
out-of-hospital cardiac arrest in the particular setting of this
investigation.
Introduction
Sudden cardiac arrest (SCA) is the leading cause of death in
the USA and Europe affecting about 750,000 people annually
[1,2]. Because of improved public training of cardiopulmonary
resuscitation (CPR) and advances in professional emergency
medical response [3], the rate of return of spontaneous circu-
lation (ROSC) has risen in the past decades. However,
depending on the duration of the arrest, neurological survival
is still a major concern [4]. The application of mild therapeutic
hypothermia (MTH) has been demonstrated to significantly
reduce neurological damage in survivors of SCA in two ran-
domised controlled trials [5,6].
Clinically, it is desirable to rely on an early and specific marker
for final neurological outcome. Protein S-100B is a potential
candidate for estimating post hypoxic neuronal damage due to
its neuronal specificity and characteristic behaviour in serum
depending on the degree of damage to the central nervous
system (CNS) [7-16]. Increased serum levels of S-100 also
have prognostic value for unfavourable neurological outcomesPage 1 of 7
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gery [17-20]. Several studies have investigated its potential
role as a prognostic marker in survivors of SCA and found it to
be a reliable marker for hypoxic/ischaemic CNS damage
[8,11,13,14,21,22]. The progressive implementation of MTH
into clinical practice and its proven impact on neurological out-
come has raised the question about its influence on serum lev-
els of S-100.
The present study was therefore conducted to elucidate the
influence of MTH on S-100 serum levels in survivors of non-
traumatic out-of-hospital cardiac arrest.
Materials and methods
During a two-year period from 2005 to 2007, 68 patients
(aged over 18 years) suffering from non-traumatic out-of-hos-
pital cardiac arrest were included in this prospective study.
Severe pre-existing conditions diagnosed in the past six
months including sepsis, stroke, previous CPR and cancer
were regarded as exclusion criteria.
CPR was performed in accordance to European Resuscitation
Council's guidelines for advanced life support 2000 [23],
which were gradually replaced by the 2005 edition [24] during
the investigation period. In general, professional emergency
medical technicians were supervised by an emergency physi-
cian on scene.
Demographic and CPR-related data were collected at the
emergency department immediately after hospital admission
and after 6, 12, 24, 72 and 120 hours at the intensive care unit
via a web-based data entry system using an Utstein-Style like
template, introduced by the German Society of Anaesthesiol-
ogy and Intensive Care Medicine [25]. Hospital admission and
first withdrawal of blood was defined as baseline.
At corresponding time points, information about haemody-
namic and metabolic parameters, such as heart rate (HR),
mean arterial pressure (MAP) and lactate and glucose levels,
as well as the proof of microbiological pathogens and whether
catecholamines were used or not, were documented. Data
about the time when MTH was started and how long MTH was
maintained were also collected. The decision to initiate MTH
was solely at the discretion of the attending physician.
At day 14, neurological outcome was assessed using the cer-
ebral performance categories (CPC) by a physician unaware
of the study. CPC 1 and 2 were regarded as favourable neu-
rological outcome, whereas CPC 3 to 5 signified adverse out-
come [26].
Because all personal data were kept anonymous and no addi-
tional blood samples were taken, the local ethics committee
approved the study without the requirement to obtain informed
consent from each patient.
Patients received standardised intensive care treatment
including mechanical ventilation, tight glucose control, infec-
tion control and vasopressor treatment to maintain MAP above
65 mmHg. Additional interventions, such as heart catheterisa-
tion, were performed if necessary.
If it was decided to cool the patient, no active warming was
applied before induction of MTH. Hypothermia was induced
via infusion of one to two litres of cold (about 6°C) saline in
combination with body surface cooling using bags filled with
ice water. To avoid shivering, patients received a continuous
intravenous infusion of non-depolarising neuromuscular-block-
ing drugs such as rocuronium or pancuronium. Although no
specific instructions were supplied by the study protocol, the
vast majority of patients nevertheless received a combined
continuous infusion of either midazolam or propofol and an
opioid. Caregivers were advised to cool down patients as fast
as possible in the induction period and to aim to achieve a core
temperature of 33°C for 24 hours and to rewarm the patient
carefully, not exceeding 1°C per hour. Core temperature was
measured with an oesophageal temperature probe, and
rewarming was usually performed with a convecting heating
blanket.
Serum samples for the determination of S-100 protein were
taken from the supernatant of blood collected for routine labo-
ratory analyses and stored at -80°C for later analysis. Serum
levels were quantified using a commercially available auto-
mated system (LIAison, DiaSorin, Dietzenbach, Germany).
To detect influences of MTH on S-100 protein levels at the
given time points, patients were grouped into those receiving
MTH or normothermia (NT). In a second analysis, this data
were evaluated regarding differences in the final CPC scores,
that is, favourable vs. adverse neurological outcome, as
defined above. Data were analysed using statistical software
SPSS 14.0 (SPSS Inc., Chicago, IL, USA). All results are
expressed as mean ± standard deviation. To establish differ-
ences between groups, analysis of variance was performed
and corrected for multiple comparisons (Bonferroni) in the
case of continuous variables. To detect changes over time,
repeated measures analysis of variance was employed and fol-
lowed by pairwise t-tests. Categorical data were analysed
using chi-squared test. P < 0.05 was considered to indicate
statistical significance.
Results
No differences between patients treated with or without MTH
were found with regard to most of the demographic and arrest-
related data (Table 1). Patients treated with MTH were signifi-
cantly more prone to bacterial infection and more often
required catecholamines. Nevertheless, these patients also
tended to have a higher in-hospital survival rate (MTH = 78.4%
vs. NT = 54.8%; P = 0.067) accompanied by a slightly more
favourable neurological outcome in comparison with the NTPage 2 of 7
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Grossly, haemodynamic and metabolic changes were compa-
rable between groups (Data not shown).
Patients treated with MTH had significantly lower oesophageal
temperatures already at baseline when compared with NT
patients (35.5°C vs. 36.4°C; P = 0.011). The target tempera-
ture of 34°C was reached within 3.0 ± 2.2 hours after hospital
admission and was maintained for 24.8 ± 4.9 hours. Lowest
values were recorded 12 hours after baseline, with mean val-
ues of 33.4 ± 0.8°C. NT patients developed sub-febrile tem-
peratures with a peak of 37.9°C at 12 hours post resuscitation
(Figure 1).
S-100 levels at baseline were significantly elevated in patients
with adverse neurological outcome (P = 0.014). This was also
true after 24 and 72 hours (Table 2).
There were no significant differences in S-100 serum levels
between NT and MTH patients at any time point (Figure 2).
Regardless of neurological outcome, S-100 serum levels were
almost congruent from six hours after ROSC in NT patients as
depicted in Figure 3. In contrast, patients treated with MTH
and a favourable neurological outcome showed a strong trend
to lower S-100 serum levels being significant after 24 hours
(CPC 1 to 2 = 0.56 vs. CPC 3 to 5 = 0.24; P = 0.001; Figure
4).
Table 1
Demographical and clinical variables of patients treated with mild therapeutic hypothermia (MTH) or normothermia (NT)
MTH (n = 37) NT (n = 31) P
Age, years 62.6 ± 15.7 67.1 ± 14.0 0.229
Sex, % male 64.7 74.2 0.442
Survival time, hours 120 ± 42 115 ± 24 0.914
Survivors, % 78.4 54.8 0.067
Good neurological outcome, % 56.8 45.2 0.341
Call-response-interval, min:sec 03:19 ± 02:26 03:05 ± 01:57 0.660
Total adrenaline, mg 4.3 ± 3.8 3.2 ± 3.8 0.286
Total shocks, n 3.5 ± 2.6 3.8 ± 5.7 0.760
Arrest witnessed, % 40.5 51.6 0.411
Initial rhythm VF, % 66.7 51.6 0.220
Cardiac origin of arrest, % 91.9 64.5 0.052
Proof of any pathogen, %* 67.6 12.9 0.001
Catecholamines at any time, %* 97.3 71.0 0.002
Core temperature at BL, °C* 35.5 36.4 0.011
Glasgow coma scale at BL 3 ± 2 4 ± 3 0.339
Results presented as mean ± standard deviation. * P < 0.05 MTH vs. NT. BL = baseline; VF = ventricular fibrillation.
Figure 1
Time course of patient's oesophageal temperature. * P < 0.05 for mild 
therapeutic hypothermia vs. normothermia. BL = baseline.Page 3 of 7
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In the present study the administration of MTH did not signifi-
cantly influence serum levels of S-100 protein in patients sur-
viving non-traumatic out-of-hospital cardiac arrest. Both
patients treated with or without MTH showed comparable
decreases in S-100 serum levels over time (Figure 2). These
findings were only marginally different when patients were
stratified according to the final neurological outcome.
S-100 protein is an astrocyte-derived neurotrophic protein
which is strongly associated with the promotion of neuronal
growth and survival [27]. It is predominately found in astro-
Table 2
S-100 Serum levels on each timepoint
Timepoint Neurological outcome P value
Good (CPC 1 to 2) Bad (CPC 3 to 5)
BL* 0.81 ± 1.09 1.93 ± 1.78 0.028
6 hours 0.47 ± 0.45 0.71 ± 0.67 0.192
12 hours 0.37 ± 0.39 0.57 ± 0.53 0.166
24 hours* 0.27 ± 0.22 0.51 ± 0.31 0.002
72 hours* 0.21 ± 0.15 0.41 ± 0.40 0.030
120 hours 0.17 ± 0.09 0.19 ± 0.10 0.669
Results presented as mean ± standard deviation. * P < 0.05 cerebral 
performance categories (CPC) 1 to 2 vs. CPC 3 to 5. BL = baseline.
Figure 2
Time course of S-100 protein. S-100 protein serum levels in patients 
receiving mild therapeutic hypothermia (MTH) vs. normothermia (NT). 
BL = baseline.
Figure 3
S-100 time course – normothermia r t r i . S-100 serum levels in patients (n = 
31) receiving normothermia (NT) for cerebral performance categories 
(CPC) 1 to 2 vs. 3 to 5. BL = baseline.
Figure 4
S-100 time course – mild therapeutic hypothermiail t r ti  t r i . S-100 serum levels 
in patients (n = 37) receiving mild therapeutic hypothermia (MTH). * P 
< 0.05 for cerebral performance categories (CPC) 1 to 2 vs. 3 to 5. BL 
= baseline.Page 4 of 7
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process of learning and memory [29]. Due to its molecular
weight of 21,000 Dalton, S-100B may only be detected in
peripheral blood if the integrity of the blood-brain barrier
(BBB) is disrupted. On the other hand, a specific lesion to the
BBB not involving the CNS may also result in elevated serum
levels [30]. Rises in S-100 serum levels are also reported from
extracerebral tissues such as marrow, fat or muscle [31].
Despite its obvious lack of specificity, it has nevertheless been
found to be an early and sensitive marker of hypoxic brain dam-
age and short-term outcome after cardiac arrest [8,10,11,13-
16,19]. Our study is in accordance with these previous reports
as at several time points patients with bad neurological out-
come had significantly higher serum levels in S-100 protein.
Remarkably, the prognostic value of S-100 for neurological
outcome in this study diminished over time. Therefore, the ini-
tial measurement shortly after admission to the hospital was
the most valuable within the post-resuscitation period.
Two previous studies have focused on the effect of therapeu-
tic hypothermia on levels of serum S-100B protein in survivors
of cardiac arrest [32,33]. Although Hachimi-Idrissi and col-
leagues [32] observed a mixed population of patients with
asystole and ventricular fibrillation (VF), the study by Tiainen
and colleagues [33] only included patients with VF, which did
not reveal a significant decline of S-100B values in MTH
patients. In contrast, Hachimi-Idrissi and colleagues found a
significant decline in MTH patients as compared with NT treat-
ment [32]. The decline was even more pronounced in patients
with asystole as initial rhythm. Because patients in our investi-
gation predominantly presented with VF as initial rhythm
(66.7% in MTH vs 51.6% in NT) our results seem to support
the notion of a connection between initial ECG and the influ-
ence of MTH on this surrogate marker.
Although we recognised a trend towards higher survival rates
as well as improved neurological outcome, we did not detect
significant improvements of these two important endpoints in
this investigation which contrasts the findings from previous
larger studies. The absolute difference of 11.6% more patients
with beneficial neurological outcome and 23.6% higher in-
hospital survival rate may nevertheless be seen as a testimony
for the potency of this intervention, even in a heterogeneous
population. However, it has to be acknowledged that in our
study patients with rhythms other than VF were also included,
which per se have lower chances of survival after cardiac
arrest [5,6].
We recognise several limitations in the interpretation of our
study. First, our results may be influenced by the relatively low
number of patients with the possibility of a lack of adequate
power to detect statistical differences. However, in prospec-
tive studies of cardiac arrest, 68 patients represent a relatively
large population. An enlargement of the study population is
nevertheless almost impossible because of an almost 100%
implementation of therapeutic hypothermia in the participating
hospitals today. Patients treated with NT will therefore
scarcely be available for recruitment.
Second, although S-100 is frequently referred to as a specific
surrogate marker for the severity of hypoxic brain injury, there
are other circumstances that may also result in elevated serum
levels. Recently, two studies suggested that serum levels may
also be elevated in children [34] as well as in adults [35] dur-
ing sepsis or septic shock, indicating a potential role of infec-
tion and inflammation in the release of S-100 protein. Due to
the high infection rate in patients receiving MTH in our study,
this might have had a certain influence on our results.
Third, the observational nature of the study which precluded
formal randomisation may have led to a systemic bias in a way
that patients with a bad prognosis may have been withdrawn
from extensive hypothermic treatment. Some of the patients
might have been actively or passively cooled before admission
to the hospital which could have directed the in-hospital car-
egivers in most cases to proceed with this therapy rather than
abolishing it. The latter might also be an explanation for the dif-
ference in temperature between MTH and NT patients at base-
line.
Finally, although at the time of the study all participating hospi-
tals were at the time of the study employing standardised
intensive care therapy, such as low tidal volume ventilation,
tight glucose control etc., the multiple centre setup can not
exclude minor differences in standard intensive care therapy or
application of MTH. Although no differences in demographic
data were evident, the favourable CPC in the MTH group
might be influenced by treating only patients with a good prog-
nosis with MTH, while others received NT. The collected out-
come data 14 days after ROSC have to be seen as medium-
term related endpoints which might not necessarily reflect
long-term results.
Conclusions
In recognising these limitations we conclude that in a mixed
population of patients with cardiac arrest, MTH had no influ-
ence on S-100 serum levels in survivors of non-traumatic out-
of-hospital cardiac arrest in the present investigation. The pre-
dictive quality of S-100 levels was best on admission but not
on later time points during the first five days of hospitalisation.
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